| NDAQ |
Report |
Adjusted EPS |
BEAT |
pred ~$0.97 vs. cons $0.95 |
MEDIUM |
| NDAQ |
Report |
Net revenue |
BEAT |
pred ~$1.45B vs. cons $1.42B |
MEDIUM |
| NDAQ |
Report |
Financial Technology ARR growth |
IN-LINE |
pred ~15% vs. cons 15% |
MEDIUM |
| NDAQ |
Guide |
Adjusted operating expense guidance |
UNCHANGED |
guide ~$2.515B midpoint vs. cons $2.515B (FY2026) |
MEDIUM |
| NDAQ |
Guide |
Financial Technology ARR growth commentary |
BETTER |
guide ~16% exit growth vs. cons 15% (H2 2026) |
LOW |
| NDAQ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.4% |
— |
MEDIUM |
| NDAQ |
Return |
5-day cumulative residual |
+1.4% (FADE) |
Day-5 residual ~+1.4% vs. day-1 ~+2.4%: strong Index and trading activity should produce a modest headline beat, but normalized Financial Technology revenue, unchanged expense guidance and limited out-period EPS revisions should partially fade the initial gain. |
MEDIUM |